Phase II Trial of Vinorelbine and Cisplatin Chemotherapy in Advanced Non - Small Cell Lung Cancer
대한암학회지 2001년 33권 5호 p.373 ~ 376
소속 상세정보
조요한/Yo Han Joh
김태유/나임일/오도연/김병수/김지현/김도연/이세훈/유철규/이준택/김영환/허대석/방영주/한성구/심영수/김노경/Tae You Kim/Im Il Na/Do Youn Oh/Byung Su Kim/Jee Hyun Kim/Do Yeun Kim/Se Hoon Lee/Chul Gyu Yoo/Choon Taek Lee/Young Whan Kim/Dae Seog Heo/Yung Jue Ban
KMID : 0360320010330050373
Abstract
PURPOSE:
Platinum-based chemotherapy has conferred a modest but significant survival benefit and the introduction of newer drugs has led to achieve higher response rate in patients with advanced non-small cell lung cancer (NSCLC). We performed a phase II trial in order to evaluate the efficacy and toxicity of combination chemotherapy with vinorelbine (Navelbine) and cisplatin in advanced NSCLC.
MATERIALS AND METHODS:
Patients with previously untreated, unresectable stage IIIB or IV NSCLC with measurable lesion (s) were eligible for entry into the study. NP chemotherapy consisted of intravenous vinorelbine 25 mg/m2, on day 1 and 8, and intravenous cisplatin 80 mg/m2 on day 1; this cycle was repeated every three weeks.
RESULTS:
A total of 33 patients were enrolled in the study between July 1999 and Feb 2000. Of the 30 patients deemed eligible for analysis, thirteen patients achieved a partial response and thirteen showed a stable disease. The overall response rate was 43.3%. The median duration of response was 5.7 months (95% CI: 2.8~8.5 months). The median time to progression was 7.6 months (95% CI: 5.5~9.7 months) and the overall median survival time was 15.1 months (95% CI: 9.8~20.4 months) in the intent-to-treat analysis. Chemotherapy-related grade 3 or 4 toxicities were anemia in 1.5%, leukopenia in 4.5%, nausea/vomiting in 2.3%, alopecia in 13.3%, and neurotoxicity in 3.3%.
CONCLUSION:
The combination of vinorelbine and cisplatin chemotherapy seems to be active and fairly tolerable in patients with advanced NSCLC.
키워드
Non-small cell lung cancer; Combination chemotherapy; Vinorelbine; Cisplatin;
원문 및 링크아웃 정보
등재저널 정보